E-DRUG: Prescrire International n°153 - October 2014
----------------------------------------------------------------------------------
PRESCRIRE INTERNATIONAL - Independent information by and for healthcare professionals
View complete contents:
http://english.prescrire.org/en/SummaryDetail.aspx?Issueid=153
In the September issue of Prescrire International:
FEATURED REVIEW:
Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome.
It has not been demonstrated that adding rivaroxaban to aspirin alone or to aspirin plus clopidogrel benefits patients who have had an acute coronary syndrome. The risk of serious and fatal bleeds is probably underestimated. Caution dictates that rivaroxaban should not be added to established antithrombotic therapy in this setting.
http://english.prescrire.org/en/81/168/49450/0/NewsDetails.aspx
FREE DOWNLOAD:
Adverse effects of boceprevir, colchicine and fluourouracil.
In this sample page from the Adverse Effects section, haematological disorders with boceprevir, deaths linked to colchicine, and dosing errors with flourouracil.
SUMMARY:
- Boceprevir: serious haematological disorders.
Monitoring blood cell counts is essential.
- Colchicine: more deaths.
Advanced age and renal failure are risk factors.
- Fluorouracil: dosing errors with infusion pumps.
Prevention includes double-checking.
http://english.prescrire.org/en/81/168/49451/0/NewsDetails.aspx
©Prescrire 1 October 2014
-----------------------------------------------------------------------------------
Prescrire is a non-profit continuing education organisation, committed to better patient care. Prescrire is financed by its subscribers. No grants, no advertising. No shareholders, no sponsors.
Subscribe today and enjoy instant access to the full database of articles in English published in Prescrire International since 1992. Subscribing online is fast and easy.
http://english.prescrire.org/en/83/178/0/0/About.aspx
-----------------------------------------------------------------------------------
Regards,
Bruno Toussaint
Publishing Director, Prescrire
Website: english.prescrire.org
contact@prescrire.org